NR546 W3 Antipsychotics Table

Drug name Indication Target symptoms: state if positive or negative effect Potency (if noted. receptor occupancy if noted ) Neurotransmitter(s) affected Half-life (T1/2), metabolism (CYP 450 enzyme) Notable side effects (associate to pathway or NT) Typical antipsychotics (conventional) Haloperidol Target symptoms: Manifestations of psychotic disorders Tics and vocal utterances in Tourette’s Syndrome Second-line treatment of severe behavior problems in children of combative, explosive, hyperexcitability Second- line short-term treatment of hyperactive children Treatment of schizophrenic patients who require prolonged parenteral antipsychotic therapy Bipolar Disorder Behavioral disturbances in dementias Delirium (with lorazepam) Positive symptoms of psychosis, violent or aggressive behavior Potency: High potency first-generation Neurotransmitter(s) affected: Blocks dopamine 2 receptors, reducing positive symptoms of psychosis and combative, explosive, and hyperactive behaviors Blocks dopamine 2 receptors in the nigrostriatal pathway, improving tics and other symptoms in Tourette’s syndrome Half-Life: Haldol decanoate: approximately 3 weeks Oral: 12-38 hours Metabolism: CYP1A2, CYP2D6, CYP3A4 • Neuroleptic-induced deficit syndrome • Akathisia • Drug-induced parkinsonism • Tardive dyskinesia, dystonia • Irreversible involuntary dyskinetic movements • Galactorrhea, amenorrhea • Dizziness, sedation • Dry mouth • Constipation • Urinary retention • Blurred vision • Decreased sweating • Hypotension • Tachycardia • Hypertension • Weight gain